Establishment of the standards for suspected drugs under drug-induced liver injury by clinical and basic study
| Project/Area Number |
25893276
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kobe Gakuin University |
|---|
Principal Investigator |
IKEMURA Mai 神戸学院大学, 薬学部, 講師 (60709278)
|
|---|
| Project Period (FY) |
2013-08-30 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 薬剤性肝障害 / ALT / 臨床 / フェニトイン / 逸脱酵素 |
|---|
| Outline of Final Research Achievements |
Drug-induced liver injury (DILI) is occasionally occurred in clinical settings. It is difficult to decide when to discontinue the suspected drugs with consideration for both the symptoms of DILI and therapeutic effects by the drugs. In this study, I evaluated the hepatic enzyme level and liver function under DILI by phenytoin, antiepileptic drug, using patients' medical records and animal models. Investigation of medical records revealed that ALT levels were fallen immediately after the discontinuation of the medication in the most of study patients, but, in some cases, it was required a lot of time to return to normal level. Experiments using murine models investigated that liver function was different in spite of the same ALT level. These results suggest that it is needed to establish the standards for a discontinuation of the suspected drugs with consideration for liver function under DILI.
|
Report
(3 results)
Research Products
(2 results)
